1 / 13

EXCELLA BD Randomized Trial 12-month Results

Explore the randomized EXCELLA-BD trial's 12-month findings on Elixir Medical's DESyne BDTM Novolimus-eluting stent system. The study demonstrates non-inferiority and superiority of the stent compared to control, indicating improved outcomes in late lumen loss and reduced restenosis rates.

jfried
Télécharger la présentation

EXCELLA BD Randomized Trial 12-month Results

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. EXCELLA BD Randomized Trial12-month Results Ricardo Costa, MD On behalf of the EXCELLA BD Investigators ••••••••Elixir Medical Confidential

  2. Elixir Medical DESyne BDTM Novolimus Eluting Coronary Stent System • DESyne BDTM • Biodegradablepolymer degrades in 6-9 months, drug release over 4 weeks • Workhorse DES that leaves behind bare metal surface • Platform features • Cobalt chromium alloy stent • 81 µm thickness • Thin polymer matrix • No primer coating • < 3µm coating thickness • Novolimus drug dose of 5 mcg per mm stent length • Active metabolite of Sirolimus

  3. EXCELLA BD Randomized Clinical Trial RANDOMIZED (3:1), SINGLE BLIND, MULTI-CENTER CLINICAL TRIAL Single/Multiple De Novo Native Coronary Artery Lesions (A-B2) Vessel Diameters: 2.5-3.5 mm Stent Diameters: 2.5-3.5 mm Lesion Length: ≤24 mm Stent Lengths: 14 - 28 mm Pre-Dilatation required/ Post-Dilatation at physicians discretion Co-Principal Investigators: A. Abizaid and S.Verheye Angiographic Core Lab: CRC IVUS Core Lab: Stanford University CEC/DSMB: CRC Data Management: CRC Cobalt Alloy Stent + Bioabsorbable Polymer + Novolimus @ 5µg per mm Stent Length Clinical Follow-up Angiographic/IVUS (Subset) Follow-up Geography: Belgium, Germany and Brazil 30d 6mo 9mo 12mo 2-5yrs DESyne BD DES n= 115 ENDEAVOR DES Control n= 31 Primary Endpoint:In-Stent Late Lumen Loss at 6 months (QCA) Device and Procedure (Clinical) Success Device-oriented composite endpoint (Death, MI, or TLR) Key Secondary Endpoints:at 1, 6, 9, 12mo and 2-5 yrs Clinically driven TLR, TVR and TVF at 1, 6, 9, 12mo and 2-5 yrs Stent thrombosis rates at 1, 6, 9, 12mo and 2-5yrs ABR, LLL and % volume obstruction at 6 months Anti-Platelet Therapy for 12 months Clinical Follow-up

  4. EXCELLA BD Study Organization • Clinical Event Committee • Aurea Chaves • Dimytri Siqueira • Sergio Braga • Angiographic Core Lab • Cardiovascular Research Center, Sao Paulo, Brazil • IVUS Core Lab • Stanford University – Peter Fitzgerald • Date Coordination Center • Cardiovascular Research Center, Sao Paulo, Brazil • Principal Investigators • Alexandre Abizaid • Stefan Verheye • Steering Committee: • Alexandre Abizaid • Stefan Verheye • Peter Fitzgerald • DSMB • OtavioBerwanger • Adriana Moreira • Ricardo Pavenello

  5. EXCELLA BD Investigators

  6. Patient Flow and Follow-up 151 patients (NL=168) enrolled and randomized Novolimus-eluting stent N=115 pts (NL=127) Zotarolimus-eluting stent N=31 pts (NL=38) 1 Deregistered 3 Withdrew consent 3 no study stent 1 Deregistered 6-day clinical FUP N=115 pts 9-month clinical FUP N=31 pts 6-month clinical FUP N=31 pts Clinical FUP 100% 6-month angio FUP N=107 pts (NL= 119) (NIVUS = 35) 6-month clinical FUP N=113 pts 6-month angio FUP N=31 pts (NL= 38) (NIVUS = 16) Clinical FUP 98.6% Angio FUP 94.5% Intention to treat analysis Pts, patients; NL number of lesions; NIVUS number of IVUS

  7. Baseline Patient Characteristics *p=0.028; all others p=ns

  8. Baseline Lesion Characteristics p=ns for all characteristics

  9. Angiographic Results 6 months

  10. Primary Endpoint Analysis: 6-month In-Stent Late Lumen Loss *Least square means Zone of non-inferiority Pre-specified margin=0.20mm Zone of Superiority Zone of non-inferiority Zone of inferiority Superior -0.20 -0.10 0.30 -0.60 -0.50 -0.40 -0.30 0.00 0.10 0.20 0.40 Upper one-sided 95% CI Met Primary Non-Inferiority Endpoint and Superiority Endpoint

  11. Clinical Results –12 months Modified Intention to Treat (patients who received a study stent)

  12. Cardiac Events at 12 months

  13. Conclusions The EXCELLA BD trial demonstrated both non-inferiority and superiority of the Elixir DESynetm BD Novolimus eluting stent compared to control for the primary endpoint of in-stent late lumen loss at 6 months Angiographic binary restenosis for the DESyne BD stent was significantly less compared to control (0.0% vs. 7.9%, p=0.003) The composite endpoint of cardiac death, TV-MI and CI-TLR remains low and unchanged from 6 months for both groups demonstrating clinical safety of the Elixir DESyne BD stent There was no reported stent thrombosis through 12 months

More Related